🧬 BioMed Pulse · 2026-11-11 02:01 UTC
BIOMED PULSE
Daily Briefing on Longevity, Viruses, and New Cures
Wednesday, November 11, 2026 | 02:00 UTC
⚡ TL;DR
The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo is now the largest Ebola outbreak ever recorded in the DRC, with sustained transmission across six provinces and confirmed imported cases in both Kenya and Nigeria as of November 6, 2026. The overall mood is tense: multiple simultaneous viral emergencies are active globally, while longevity science points to promising but still early interventions around muscle aging and AI-driven biological age assessment.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS DISEASE (EBOLA) - DRC, KENYA, NIGERIA
- As of November 6, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has expanded geographically, with some areas reporting a slight decline but sustained, high-level transmission continuing across the country. [1]
- The outbreak has spread across six of 26 provinces in the DRC: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, plus the newly affected province of Sud Ubangi in the north-west. [2]
- An imported BVD case was confirmed in Kenya on October 5, 2026, in a patient who traveled from DRC through Uganda; both Kenya and Nigeria have since reported imported cases. [3] [4]
- As of the October 23 WHO Disease Outbreak News update, sustained, high-level transmission characterized the outbreak across the DRC, with geographic expansion continuing into neighboring countries. [4]
- For context on scale: as of August 14, 2026, WHO described this as the largest Ebola outbreak ever reported in the DRC and noted it was expanding faster than any previous Ebola outbreak. [5]
- CDC has had enhanced Ebola airport screening running at Washington Dulles and Atlanta Hartsfield-Jackson airports since late May 2026 in response to this outbreak. [6] [7]
SHAMONDA VIRUS - FRANCE (FIRST DOCUMENTED HUMAN CASE)
- On October 20, 2026, France notified WHO of the first ever documented human infection with Shamonda virus (SHAV), a WHO Disease Outbreak News first. [8]
- The case was an immunocompromised older man from eastern France with no recent travel history who developed severe neurological symptoms. [8]
- Shamonda virus is a Simbu serogroup orthobunyavirus previously known only from livestock and insects in Africa and parts of Europe; this is a significant species jump event under investigation. [8]
YELLOW FEVER - WHO AFRICAN REGION
- Between January 1 and October 12, 2026, WHO's African Region recorded 67 confirmed yellow fever cases including 18 deaths across nine countries: Burkina Faso, Cameroon, Central African Republic, and six others in West Africa. [9]
- Transmission activity in the Americas also persisted into 2026, with six countries reporting 79 human infections between January 1 and May 26, 2026. [10]
MERS-CoV - SAUDI ARABIA
- Between January 1 and October 5, 2026, Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases including one death, detected across six locations including Riyadh and Tabuk.
NIPAH VIRUS - INDIA
- On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus case in Kozhikode district: an adult male who developed neurological symptoms starting May 30, 2026.
PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA
- On October 2, 2026, WHO was alerted via media reports to the death of an employee of the Irkutsk Antiplague Research Institute of Siberia and the Far East, who died from severe pneumonia of undetermined cause.
- The patient was a researcher at a facility that handles dangerous pathogens, raising biosafety questions currently under investigation.
HANTAVIRUS (ANDES VIRUS) - CRUISE SHIP M/V HONDIUS
- The Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius, first notified to WHO on May 2, 2026, was still being tracked as of the July 2, 2026 WHO Disease Outbreak News fifth posting.
🧬 LONGEVITY & AGING
GDF11 AND MUSCLE AGING / SARCOPENIA
- A study published in Genes & Disease (Zhang F., February 2026) found that GDF11, a circulating blood factor, restores skeletal muscle satellite cell function via the MYC transcription factor, ameliorating sarcopenia, the age-related muscle-wasting condition that affects hundreds of millions of older adults.
- Satellite cells are the resident stem cells of skeletal muscle; their declining activity with age is a key driver of frailty, and GDF11-MYC signaling represents a potential therapeutic axis.
AI FACE-PHOTOGRAPH BIOLOGICAL AGE MODEL
- A model development and validation study published in Lancet Digital Health (Haugg F., Lee G., He J., Gladyshev VN., Aerts HJ., Mak RH., et al.) introduced FAHR-Face, a foundation AI model that estimates biological age from face photographs.
- The model incorporated Vadim Gladyshev's lab (Harvard) alongside teams from Dana-Farber and Maastricht, underscoring the convergence of aging biology and clinical AI.
AI CARDIAC MRI AND MORTALITY PREDICTION
- A separate retrospective multicentre prognostic study in Lancet Digital Health (Joy G., Moon JC., Davies RH., et al.) showed that AI left-ventricular segmentation of cardiac MRI outperformed clinician segmentation in predicting mortality, relevant to aging populations with high rates of heart failure.
STATIN DISCONTINUATION AND FRAILTY IN OLDER ADULTS
- A population-wide retrospective cohort study in England using Clinical Practice Research Datalink data (Seeley AE., Sheppard JP., et al., Lancet Healthy Longevity) examined the efficacy and safety of stopping statins in patients 65 and older, stratified by frailty status.
- An accompanying editorial (Bardoczi JB., Rodondi N.) highlighted the clinical importance of frailty assessment before deprescribing statins, since frailty modifies both cardiovascular risk and drug tolerance in older patients.
ANIMAL PROTEIN, COGNITIVE AGING, AND DEMENTIA SEX DISPARITIES
- A global ecological analysis in Future Science OA (You W., Henneberg M., et al., published November 2, 2026) examined the relationship between national animal protein supply, cognitive aging trajectories, and female-male dementia incidence disparities, finding that protein supply patterns correlate with population-level cognitive aging differences.
OLDER ADULTS IN HUMANITARIAN CRISES: A LONGEVITY EQUITY SIGNAL
- A coordinated series of papers in Lancet Healthy Longevity (de la Fuente-Núñez V., Escobio F., van Boetzelaer E., et al.) documented that older adults are systematically overlooked in humanitarian emergency health responses, creating acute longevity equity gaps.
- Specific gaps highlighted include malnutrition (Lelijveld N. et al.), absence of palliative care (Escobio F. et al.), and lack of sexual and reproductive health services for older persons in crisis settings.
💊 NEW CURES & APPROVALS
ORGOVYX (RELUGOLIX) - SUMITOMO PHARMA AMERICA (SUPPLEMENTAL APPROVAL)
- Orgovyx, whose active ingredient is relugolix (a GnRH receptor antagonist for androgen deprivation therapy in advanced prostate cancer), received a supplemental approval from openFDA under NDA214621, sponsor Sumitomo Pharma America.
ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) - ADC THERAPEUTICS SA (SUPPLEMENTAL APPROVAL)
- Zynlonta, an antibody-drug conjugate (ADC) targeting CD19 for relapsed or refractory large B-cell lymphoma, received a supplemental approval under BLA761196, sponsor ADC Therapeutics SA.
RYBREVANT FASPRO (AMIVANTAMAB + HYALURONIDASE-LPUJ) - JANSSEN BIOTECH (SUPPLEMENTAL APPROVAL)
- Rybrevant Faspro, a subcutaneous formulation combining the EGFR/MET bispecific antibody amivantamab with hyaluronidase, received a supplemental approval under BLA761433, sponsor Janssen Biotech, for EGFR-mutant non-small cell lung cancer.
RELEUKO (FILGRASTIM-AYOW) - KASHIV BIOSCIENCES LLC (SUPPLEMENTAL APPROVAL)
- Releuko, a filgrastim biosimilar (G-CSF, used to stimulate white blood cell production after chemotherapy), received a supplemental approval under BLA761082, sponsor Kashiv Biosciences LLC.
AMJEVITA (ADALIMUMAB-ATTO) - AMGEN INC (SUPPLEMENTAL APPROVAL)
- Amjevita, an adalimumab biosimilar (anti-TNF-alpha) used across multiple inflammatory conditions, received a supplemental approval under BLA761024, sponsor Amgen Inc.
FLUTICASONE PROPIONATE - TEVA PHARMACEUTICALS USA INC (ORIGINAL APPROVAL)
- Teva's fluticasone propionate inhaled corticosteroid received an original approval (ORIG AP) under ANDA209917 for respiratory indications.
OLOPATADINE HYDROCHLORIDE - ALEMBIC (ORIGINAL APPROVAL)
- Alembic received an original approval for olopatadine hydrochloride (an antihistamine/mast cell stabilizer for allergic conjunctivitis) under ANDA217856.
🧪 CLINICAL TRIALS
RSV HUMAN CHALLENGE STUDY IN OLDER ADULTS AGED 65-75
- A new controlled human infection study (NCT07713628) opened November 10, 2026, enrolling 20 non-smoking healthy adults aged 65 to 75 to characterize immune responses to RSV B challenge; it uses a sentinel cohort of 6 participants before full enrollment proceeds.
- This study directly addresses immune senescence in the context of RSV, the leading cause of respiratory hospitalization in older adults.
PSILOCYBIN PLUS COGNITIVE TRAINING FOR NEUROPLASTICITY IN AGING (NCT07721467)
- A trial posted November 10, 2026 (NCT07721467) is investigating whether psilocybin can enhance neuroplasticity when combined with structured cognitive training in older adults with or without early Alzheimer's disease-related changes.
- The rationale is that psilocybin's serotonin 2A receptor agonism may open synaptic plasticity windows that cognitive training can exploit, potentially slowing dementia progression.
VACCINE IMMUNE RESPONSE IN AGING AND FRAILTY (NCT05291676)
- An ongoing systems immunology trial (NCT05291676, updated November 10, 2026) is comparing immunologic, transcriptomic, and metabolomic response signatures to Fluad versus Fluzone High-Dose in adults aged 65 and over.
- Results will help clarify whether high-dose or adjuvanted influenza vaccines confer superior protection in frail versus non-frail older adults.
PLANT-BASED DIETS AND HEALTHY AGING IN TAIWAN (NCT07151365)
- A prospective study (NCT07151365) is enrolling 5,000 Tzu Chi volunteers in Taiwan to track health outcomes of vegetarian and plant-based diets in middle-aged and older adults, building on prior Tzu Chi cohort data linking vegetarian diets to lower rates of diabetes and stroke.
GENE TRANSFER FOR LATE ONSET POMPE DISEASE (NCT04174105)
- A Phase 1/2 open-label ascending dose multicenter trial (NCT04174105) is evaluating AT845, an AAV gene therapy, for safety and efficacy in adults with Late Onset Pompe Disease (LOPD), a progressive lysosomal storage disorder causing muscle weakness in aging adults.
📢 PUBLIC HEALTH
DRUG-RESISTANT BACTERIA RISING SHARPLY IN THE U.S.
- A CDC report released September 23, 2025, documented a dramatic increase in a dangerous type of drug-resistant bacteria in the United States, adding urgency to antimicrobial stewardship efforts.
NEWBORN SYPHILIS RISES FOR 12TH CONSECUTIVE YEAR
- CDC data released September 24, 2025, showed U.S. congenital syphilis cases increased for a 12th consecutive year in 2024, a persistent maternal and infant health failure.
LISTERIA OUTBREAK IN PREPARED MEALS - ONGOING
- As of October 30, 2025, CDC continued to report new Listeria illnesses despite multiple product recalls linked to prepared meals, urging consumers to check refrigerators and freezers for recalled foods.
SALMONELLA IN MORINGA LEAF PRODUCTS - ONGOING MULTI-OUTBREAK ALERT
- An extensively drug-resistant Salmonella outbreak linked to moringa powder capsules was updated as recently as February 2026, with a cumulative 65 people sick in 28 states as of January 29, 2026; the moringa Salmonella problem has generated multiple separate outbreak investigations since late 2025.
CDC BIOSURVEILLANCE: 1 MILLION AIR TRAVELERS ENROLLED
- CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary participants as of January 30, 2026, a significant expansion in real-time pathogen detection capacity at U.S. ports of entry.
U.S. WHO WITHDRAWAL COMPLETED
- The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and politicization, with the administration announcing a shift toward bilateral health efforts.
BIOMED PULSE is an informational briefing only and does not constitute medical advice. All information is drawn from official public sources as cited. Consult a qualified healthcare professional for personal health decisions.
📎 Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
- Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
- Shamonda virus in human - France — WHO Disease Outbreak News
- Yellow fever - WHO African Region — WHO Disease Outbreak News
- Yellow fever - Global — WHO Disease Outbreak News
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261111-02-v133 · 2026-11-11 02:01 UTC · pulse.uzylab.com